Tenapanor 5 mg BID

Phase 3

Ardelyx (ARDX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Feb '27

ARDXPhase 3$1.5B

Tenapanor 5 mg BID Phase 3 Est. Readout

Tenapanor 5 mg BID• Chronic Idiopathic Constipation (CIC)692

Feb 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Chronic Idiopathic Constipation (CIC)

View Full Landscape

Drug Information

Target Indication

Chronic Idiopathic Constipation (CIC)

Clinical Trial

NCT07382167

Last updated: 2/3/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ARDX

Ardelyx

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Phosphate Binder AgentsPhase 3

Hyperphosphatemia

Tenapanor 50 MGPhase 3

Irritable Bowel Syndrome With Constipation (IBS-C)

Sevelamer CarbonatePhase 3

Hyperphosphatemia

TenapanorPhase 3

Hyperphosphatemia

AZD1722Phase 3

Chronic Kidney Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts